Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Kallyope Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across distinct art units, suggesting that the filings cover different specialized biological or pharmaceutical classifications. The prosecution involves 2 distinct examiners, meaning each examiner is currently handling a single pending office action. This distribution shows that the company's active matters are not concentrated under a single individual.
GYAN CHANDRA is the busiest examiner for this portfolio, with 1 pending office action under review. This workload is equal to the other of the distinct examiners involved in the company's prosecution. The presence of distinct art units for the active matters indicates that each is being evaluated by a different technical group within the office. This profile suggests a diversified approach to the Biotechnology & Pharmaceuticals field, even with a small number of active matters. Practitioners should be prepared for different examination styles across the assigned art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| REILLY, SOPHIA JANE | 1 | 60.8% | +49.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | CHANDRA, GYAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285812 | GPR119 AGONISTS | REILLY, SOPHIA JANE | 30d |
| 19415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | CHANDRA, GYAN | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | CHANDRA, GYAN | 1674 | §103§112 | Non-Final OA | — | Pending | Dec 10, 2025 |
| 18285812 | GPR119 AGONISTS | REILLY, SOPHIA JANE | 1627 | §112 | Non-Final OA | 30d | Pending | Oct 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial